Blockchain Registration Transaction Record

Kairos Pharma's Prostate Cancer Therapy Shows Breakthrough 13+ Month Survival

Kairos Pharma's ENV105 shows 13+ month survival in prostate cancer trial, exceeding targets with no toxicities. Breakthrough treatment addresses drug resistance.

This development represents a potential paradigm shift in treating metastatic castration-resistant prostate cancer, one of the most challenging forms of prostate cancer with limited treatment options. For patients facing this aggressive disease, the combination therapy's demonstrated progression-free survival of over 13 months—more than triple the current standard—could significantly extend life expectancy while maintaining quality of life. The well-tolerated nature of the treatment without dose-limiting toxicities addresses a critical need for therapies that are both effective and manageable for patients undergoing cancer treatment. This breakthrough could eventually benefit thousands of patients worldwide and represents important progress in overcoming treatment resistance, a major hurdle in oncology.